Liane R. Teplitsky was named Chief Operating Officer of Pulse Biosciences, Inc., effective April 8, 2026. As of November 6, 2026, Pulse Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 9, 2026, naming 1 appointment (Form 8-K, April 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Pulse Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Pulse Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Pulse Biosciences, Inc. files it.
Also on the record for Pulse Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 13, 2026 | Stake report, Schedule 13D/A, by ROBERT W. DUGGAN | 71.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Pulse Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Pulse Biosciences, Inc. and the records around it.
Pulse Biosciences, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Watch Pulse Biosciences, Inc.
Get an email when Pulse Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pulse Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pulse Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pulse Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-09 | In | Chief Operating Officer | 2026-04-08 | 8-K, 2026-04-09 |
Who leads Pulse Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Operating Officer: Liane R. Teplitsky, appointed, effective 2026-04-08 (filed 2026-04-09).
New leaders reset buying decisions — get the Full Report on Pulse Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Pulse Biosciences, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Pulse Biosciences, Inc.Every change, in the filing's words
Appointed: Liane R. Teplitsky, Chief Operating Officer, effective 2026-04-08
Chief Operating Officer Appointment Pulse Biosciences, Inc. (the "Company") has appointed Liane R. Teplitsky as its Chief Operating Officer, effective as of April 8, 2026 (the "Start Date").
- Ms. Teplitsky most recently served as Chief Executive Officer of Artedrone, where she led the strategy and development of an autonomous robotic technology for stroke treatment.
- Previously, Ms. Teplitsky held senior marketing and commercial leadership roles at Abbott Laboratories and St. Jude Medical, contributing to the development, clinical validation, and global commercialization of cardiovascular and electrophysiology (EP) therapies.
- She also served as President of Robotics, Technology and Data Solutions at Zimmer Biomet, where she led global strategy and commercialization for robotics and digital health technologies.
- Ms. Teplitsky holds a Master of Science in Biomedical Engineering from Duke University and Bachelor of Science degrees in Electrical Engineering and Physiology from the University of Saskatchewan.
- Ms. Teplitsky currently serves as Chairman of the Board of Carvolix (Paris-EUR) and will remain in this role as she joins Pulse Biosciences.
- Employment Agreement and Other Compensatory Arrangements In connection with Ms. Teplitsky's appointment as Chief Operating Officer, the Company and Ms. Teplitsky entered into an Employment Agreement, dated April 8, 2026 (the "Employment Agreement"), pursuant to which Ms. Teplitsky will serve as the Company's Chief Operating Officer.
- The material terms and conditions of the Employment Agreement are summarized below.
Tools for this story
Each opens in a new tab, filled in for Pulse Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.